DGX vs CRL — Key Metrics

Metric DGX (QUEST DIAGNOSTICS INC) CRL (CHARLES RIVER LABORATORIES INTERNATIONAL INC)
Price259.69333.25
Market Cap28.57 Billion15.97 Billion
P/E (TTM)25.51311.45
P/B (Quarterly)3.4874.845
P/S (TTM)2.414.02
Net Profit Margin (TTM)9.51.0
Gross Margin (TTM)33.133.3
ROE (TTM)15.21.3
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

QUEST DIAGNOSTICS INC
vs
 
CHARLES RIVER LABORATORIES INTERNATIONAL INC
 
QUEST DIAGNOSTICS INC
vs
 
CHARLES RIVER LABORATORIES INTERNATIONAL INC
Performance Comparison
AI Model Recommendation
DGX · QUEST DIAGNOSTICS INC

Underperform

-8
UnderperformOutperform
CRL · CHARLES RIVER LABORATORIES INTERNATIONAL INC

Greatly Underperform

-80
UnderperformOutperform
Recommendation Summary

Stock DGX is projected to underperform the market, stock CRL is projected to greatly underperform the market. Upfront Recommendation: DGX.

Financial Metrics
Prices delayed ~15 min
DGX Metrics CRL
$259.69 Price $333.25
— Market Capitalization —
25.51 Price to Earnings Ratio 311.45
2.41 Price to Sales 4.02
20.78 Price to FCF Ratio 39.96
7.29 Price to Gross Profit 12.05
9.17 Price to Current Assets 10.4

DGX vs CRL at a glance

Quest Diagnostics INC (DGX) and Charles River Laboratories International INC (CRL) are both Diagnostics & Research companies in the Healthcare sector. DGX is the larger, at $28.6 billion in market value against $16.0 billion for CRL, about 1.8 times the size.

On trailing-twelve-month figures, DGX trades at 25.5 times trailing earnings and CRL at 311.4; net profit margins are 9.5% and 1.0%.

The Upfront Investment model currently rates DGX Underperform and CRL Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.